Studies have shown that [21, 22] overexpression of CT45A1 in breast cancer cells significantly upregulates several oncogenic and metastatic genes, indicating that CT45A1 may be a promising biomarker for targeted tumor therapy [21]. This evidence concerns the gene CT45A1 and neoplasm.